Celera links up with LabCorp and Quest:
This article was originally published in Clinica
Executive Summary
Celera Diagnostics has formed separate deals with Laboratory Corporation of America (LabCorp) and Quest Diagnostics to collaborate on tests for a number of common diseases. The agreement with LabCorp is expected to lead to tests for Alzheimer's disease, breast cancer and prostate cancer. The deal with Quest provides for the development of tests for cardiovascular disease and diabetes. The collaborations will support current and future disease association studies at Celera that seek to identify genetic markers associated with the diseases. Alameda, California-based Celera will be the preferred vendor to LabCorp and Quest for certain molecular diagnostic products.